Abelacimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | Factor XIand its active form Factor XIa |
| Clinical data | |
| Other names | MAA868 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
Abelacimab(MAA868), is a fully humanmonoclonal antibodyfor the treatment ofcoagulation,[1]under development byAnthos Therapeutics.
Mechanism of action
[edit]It isanti-factor XIantibody.[1][2]
See also
[edit]
References
[edit]- ^abVerhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Büller HR, et al. (August 2021)."Abelacimab for Prevention of Venous Thromboembolism".The New England Journal of Medicine.385(7): 609–617.doi:10.1056/NEJMoa2105872.PMID34297496.S2CID236198598.
- ^"Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)".Business Wire.18 September 2023.
 | Thismonoclonal antibody–related article is astub.You can help Wikipedia byexpanding it. |
 | Thisdrugarticle relating to thebloodandblood forming organsis astub.You can help Wikipedia byexpanding it. |